Production (Stage)
NurExone Biologic Inc.
NRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 43.01% | 48.37% | 24.47% | 35.84% | -3.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.97% | 36.90% | 12.08% | 14.19% | -4.27% |
| Operating Income | -49.97% | -36.90% | -12.08% | -14.19% | 4.27% |
| Income Before Tax | -50.35% | -38.54% | -8.09% | -9.00% | 41.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.35% | -38.54% | -8.09% | -9.00% | 41.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.35% | -38.54% | -8.09% | -9.00% | 41.20% |
| EBIT | -49.97% | -36.90% | -12.08% | -14.19% | 4.27% |
| EBITDA | -49.37% | -36.54% | -11.70% | -13.30% | 5.06% |
| EPS Basic | -3.88% | 4.23% | 20.18% | 14.67% | 55.31% |
| Normalized Basic EPS | -4.08% | 3.88% | 20.18% | 13.84% | 32.24% |
| EPS Diluted | -3.88% | 4.23% | 20.18% | 14.67% | 55.31% |
| Normalized Diluted EPS | -4.08% | 3.88% | 20.18% | 13.84% | 32.24% |
| Average Basic Shares Outstanding | 41.06% | 42.30% | 33.69% | 27.58% | 23.76% |
| Average Diluted Shares Outstanding | 41.06% | 42.30% | 33.69% | 27.58% | 23.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |